MA50504A - Composés antibactériens - Google Patents

Composés antibactériens

Info

Publication number
MA50504A
MA50504A MA050504A MA50504A MA50504A MA 50504 A MA50504 A MA 50504A MA 050504 A MA050504 A MA 050504A MA 50504 A MA50504 A MA 50504A MA 50504 A MA50504 A MA 50504A
Authority
MA
Morocco
Prior art keywords
antibacterial compounds
antibacterial
compounds
Prior art date
Application number
MA050504A
Other languages
English (en)
Inventor
Cedric Charrier
Nawaz Khan
Paul Meo
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of MA50504A publication Critical patent/MA50504A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Warehouses Or Storage Devices (AREA)
MA050504A 2017-11-03 2018-11-02 Composés antibactériens MA50504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds

Publications (1)

Publication Number Publication Date
MA50504A true MA50504A (fr) 2020-09-09

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050504A MA50504A (fr) 2017-11-03 2018-11-02 Composés antibactériens

Country Status (22)

Country Link
US (2) US11345694B2 (fr)
EP (2) EP3704105B9 (fr)
JP (2) JP7348897B2 (fr)
KR (1) KR102470319B1 (fr)
CN (1) CN111566099B (fr)
AU (1) AU2018361828B2 (fr)
BR (1) BR112020008531A2 (fr)
CA (1) CA3081423A1 (fr)
CL (2) CL2020001147A1 (fr)
CO (1) CO2020005420A2 (fr)
EA (1) EA202091118A1 (fr)
ES (1) ES3005164T3 (fr)
GB (1) GB201718285D0 (fr)
GE (2) GEP20237522B (fr)
IL (1) IL274229B2 (fr)
MA (1) MA50504A (fr)
MX (2) MX2020004562A (fr)
PE (2) PE20211390A1 (fr)
SG (1) SG11202003717UA (fr)
UA (1) UA128475C2 (fr)
WO (1) WO2019086890A1 (fr)
ZA (1) ZA202002093B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
CN117597337A (zh) * 2021-05-03 2024-02-23 迪斯库瓦有限公司 抗菌化合物的制备方法
US20240228474A1 (en) * 2021-05-03 2024-07-11 Discuva Limited Antibacterial compound
JP7807529B2 (ja) 2022-02-21 2026-01-27 三井化学株式会社 金属部材、金属樹脂接合体及び金属部材の製造方法
CN118164937A (zh) * 2024-03-13 2024-06-11 北京联本医药化学技术有限公司 一种铵盐离子液体催化制备5-乙酰基-2,3-苯丙二氢呋喃的方法
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物
CN121471219A (zh) * 2026-01-09 2026-02-06 四川大学 用于革兰氏阴性菌特异性抗菌治疗的咪唑-2-胺类衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1532118A2 (fr) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Composes d'imidazole pour le traitement des infections par le virus de l'hepatite c
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
US7678810B2 (en) * 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (fr) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Composé, compositions et procédés de lutte contre les biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (fr) 2011-03-25 2012-10-04 North Carolina State University Inhibition de biofilms bactériens et croissance microbienne avec des dérivés d'imidazole
AU2012281281B2 (en) 2011-07-13 2017-06-01 Tiumbio Co., Ltd 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
WO2015173788A1 (fr) * 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Nouvelle stratégie anti-infectieuse contre le virus de la grippe et les co-infections par s. aureus
PE20171789A1 (es) 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
WO2016141381A2 (fr) 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentialisateurs d'antibiotiques bêta-lactames
EP3325473A4 (fr) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Composés et leurs utilisations dans le traitement de cancers et d'autres états médicaux
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
IL274229B1 (en) 2023-01-01
CA3081423A1 (fr) 2019-05-09
BR112020008531A2 (pt) 2020-10-20
ES3005164T3 (en) 2025-03-14
US20210163460A1 (en) 2021-06-03
IL274229A (en) 2020-06-30
JP2021501756A (ja) 2021-01-21
PE20211390A1 (es) 2021-07-27
IL274229B2 (en) 2023-05-01
KR20200084875A (ko) 2020-07-13
KR102470319B1 (ko) 2022-11-25
SG11202003717UA (en) 2020-05-28
AU2018361828A1 (en) 2020-05-28
EP4606375A2 (fr) 2025-08-27
CL2020001147A1 (es) 2020-08-14
UA128475C2 (uk) 2024-07-24
ZA202002093B (en) 2023-11-29
CO2020005420A2 (es) 2020-07-31
ES3005164T9 (en) 2025-03-24
GEAP202315801A (en) 2023-03-27
GB201718285D0 (en) 2017-12-20
MX2021010246A (es) 2021-09-21
EP3704105B1 (fr) 2024-10-16
JP2022025116A (ja) 2022-02-09
AU2018361828B2 (en) 2023-05-18
EA202091118A1 (ru) 2020-08-06
MX2020004562A (es) 2020-08-13
EP3704105A1 (fr) 2020-09-09
WO2019086890A1 (fr) 2019-05-09
NZ764310A (en) 2023-04-28
US20220372027A1 (en) 2022-11-24
JP7348897B2 (ja) 2023-09-21
US11345694B2 (en) 2022-05-31
CL2021002263A1 (es) 2022-04-01
CN111566099A (zh) 2020-08-21
EP3704105B9 (fr) 2025-03-05
EP4606375A3 (fr) 2025-11-19
PE20221006A1 (es) 2022-06-15
CN111566099B (zh) 2023-06-02
GEP20237522B (en) 2023-08-10

Similar Documents

Publication Publication Date Title
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
MA42293A (fr) Composés antibactériens
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
MA53003A (fr) Composés
MA44020A (fr) Composés antitumoraux
ME03419B (fr) Composés dihydroisoquinolinone substitués
EP3853210A4 (fr) Composés antibactériens
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
LT3468975T (lt) Nauji antibakteriniai junginiai
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
GB201718285D0 (en) Antibacterial Compounds
MA52946A (fr) Composés
EP3310352A4 (fr) Composés cristallins
EP3458041A4 (fr) Compositions antibactériennes
EP3717483A4 (fr) Composés de pyrazolopyridinone
EP3713941A4 (fr) Composés de pyrazolopyridinone
MA49522A (fr) Nouveaux composés de quinoléinone
MA49885A (fr) Composés macrocycliques
DK3672941T3 (da) Pyridylpyridonforbindelser